Hisamitsu Pharma launches Salonpas® Diclofenac Patch 1% in Singapore for pain relief
Japanese patch drug powerhouse Hisamitsu Pharmaceutical was slapped with a business suspension order on August 12 for falsifying data in the manufacturing process of one of the OTC products among its mainstay Salonpas series of topical anti-inflammatory analgesics. The government…
MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch formulation approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia, is now available by prescription in the U.S.1
Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration (FDA) for its transdermal schizophrenia patch.
Noven Pharma, Hisamitsu Pharma sue Mylan on generic Minivelle